Ovarian Cancer :: New Therapy for Patients with Platinum-Resistant Ovarian Cancer

Mayo Clinic reported promising interim results from a Phase II trial of a new combination therapy for patients with recurrent ovarian cancer that is resistant to platinum therapy. Thirty-three percent of study participants achieved either complete or partial tumor regression from the therapy, which combines flavopiridol and cisplatin.

Lung Cancer :: Study identifies novel gene alterations in lung cancer

An international team of scientists, supported in part by the National Human Genome Research Institute (NHGRI), one of the National Institutes of Health (NIH), announced that its systematic effort to map the genomic changes underlying lung cancer has uncovered a critical gene alteration not previously linked to any form of cancer. The research, published in the advance online issue of the journal Nature, also revealed more than 50 genomic regions that are frequently gained or lost in lung adenocarcinoma, the most common type of lung cancer in the United States.

Ovarian Cancer :: Novel medication improves ovarian cancer treatment

A new study appearing in International Journal of Gynecological Cancer states that Bevacizumab, a biologic anti-cancer agent that prevents tumor growth by interfering with the formation of new blood vessels, may have the potential to improve the efficacy of standard combination chemotherapy in ovarian cancer.

Ovarian Cancer :: Study fuels debate over whether exercise and body size influence ovarian cancer risk

A new study adds fuel to the debate over whether being fat or inactive affects the risk of developing ovarian cancer. The study, presented by Australian researchers today (Thursday) at the European Cancer Conference (ECCO 14) in Barcelona, found some evidence suggesting exercise might increase the risk. It found no link with body measurements.